Drug Approval | November 06, 2025
Bayer's finerenone approved in India for heart failure
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
AI-powered cardiometabolic wellness platform for India’s workforce
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Tourmaline is now an indirect wholly owned subsidiary of Novartis
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Subscribe To Our Newsletter & Stay Updated
